tbuckley/cabot-search huggingface dataset:
A successful treatment of an intrarenal arteriovenous fistula by percutaneous embolization
Authors: J Winkler, M Neuman-Levin, G Boner
Journal: JAMA (1991)

A 37-year-old woman patient, known to have poorly controlled arterial hypertension that was diagnosed following a cerebrovascular accident at the age of 15 years, was referred to our outpatient clinic for investigation in 1987. An intrarenal arteriovenous fistula was diagnosed by selective renal angiography. Embolization of the fistula was performed using four 15-mm/5-cm coils, which induced thrombosis and obstructed the fistula. The vascularization of the affected kidney improved immediately. During the following 4 months, the antihypertensive treatment was stopped gradually, and the patient remained normotensive. This is an unusual case of a large intrarenal arteriovenous fistula, whose etiology was not clear, that was successfully treated by percutaneous embolization. (<i>JAMA</i>. 1991;265:631-632)
Journal Delivery
Authors: Martin C. Flohr
Journal: JAMA (1974)

<h3>To the Editor.—</h3> May I comment on the marvelous and efficient results of our now nongovernmental postal service? On April 8, I received the issues ofThe Journalfor 29 March and 8 April in the same mail. Today, the issues of 15 April and 22 April arrive together. Such is progress? Oh! For the "good old days" of interested and efficient postal employees.
The Patient and the Plastic Surgeon
Authors: Richard Carlton Schultz
Journal: JAMA (1982)

This unillustrated monograph is an unusual book. It deals with the ethics and pitfalls of plastic surgery, how to interview, and how to deal with patients' problems in the most humanistic manner. In the preface the author clearly addresses himself to the plastic surgeon, but much of the book deals with what should be patently obvious and common knowledge to one fully trained in this field. Because of its clear writing and irrefutable truths, it could perhaps be used more profitably by physicians referring patients to plastic surgeons, or by medical students and hospital nurses regularly dealing with plastic surgery patients. Dr Goldwyn is editor of the superb journal<i>Plastic and Reconstructive Surgery</i>, as well as author of numerous fine books in the field of plastic surgery. He is obviously a seasoned and highly skilled medical author. In this book, however, he is sometimes lyrical, frequently pontificates, resorts regularly to
Intercellular Transmission of Hepatic ER Stress in Obesity Disrupts Systemic Metabolism
Authors: Amir Tirosh, Gurol Tuncman, Ediz S. Calay, Moran Rathaus, Idit Ron, Amit Tirosh, Abdullah Yalcin, Yankun G. Lee, Rinat Livne, Sophie Ron, Neri Minsky, Ana Paula Arruda, Gökhan S. Hotamisligil
Journal: Cell Metabolism (2021)
PUBLIC HEALTH.
Authors: J. Courtney Hixson
Journal: JAMA (1895)

Medical Jurisprudence.-Examination viva voce.Personal identity ; Age, Sex.Medico-legal relations of Pregnancy and Parturition.Signs of Death ; Wounds and other inju¬ ries ; detection of Blood.The Commoner Poisons (not in¬ cluding their detection by Chemic Analysis).Laic.-Examination by paper.Time one andone-half hours.
AKESIS UNIVERSALIS.
Authors: George R. Center
Journal: JAMA (1884)

tient, and is the sequence of exhausting disease, and the consequence of some overpowering influence upon the brain, either from without or within, and,as I have thought,the expression of some disease the ex¬ tent of which could be clearly defined.But, my dear friend, I have failed utterly to find any cause for anything of the kind.Here is a man apparently in full vigor, in the prime of life, attacked
Climate change and human survival
Journal: BMJ (2014)

The release of just another 275 gigatonnes of carbon dioxide would probably commit us to a temperature rise of at least 2°C-an amount that could be emitted in less than eight years."Instead the text should have read, "The release of just another 275 gigatonnes of carbon would probably commit us to a temperature rise of at least 2°C-an amount that could be emitted in less than 25 years.
Scientific status of refreshing recollection by the use of hypnosis. Council on Scientific Affairs
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HOW TO RELAX
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editors, Contents, Cover details
Authors: Rebecca Schwarzlose, Susanne Brink, Paige Shaklee, Rolf Van Der Sanden, Ria Otten, Patrick Scheffmann, Ralph Adolphs, Renee Baillargeon, Nick Chater, Peter Dayan, Stanislas Dehaene, Daniel Dennett, Yadin Dudai, Andreas Engel, Martha Farah, Angela Friederici, Okihide Hikosaka, Ray Jackendoff, Philip Johnson-Laird, Nancy Kanwisher, Christof Koch, Marta Kutas, Nikos Logothetis, James Mcclelland, Earl Miller, Elizabeth Phelps, Russell Poldrack, Marcus Raichle, Trevor Robbins, Anthony Wagner, Vincent Walsh, Christopher Smith
Journal: Trends in Cognitive Sciences (2017)
Abdur Razzaq
Authors: Furhan Razzaq, Rubeena Razzaq
Journal: BMJ (2015)

<h3>Objective</h3> Adherence to attention-deficit/hyperactivity disorder (ADHD) medication treatment is often suboptimal. This can compromise patient outcomes. We aimed to describe the patterns of ADHD medication use in Australian children, and characteristics associated with patterns of use. <h3>Design</h3> Dispensing data were analysed for all redeemed prescriptions of methylphenidate, dexamphetamine and atomoxetine between May 2002 and March 2015 from waves 1 to 6 of the Longitudinal Study of Australian Children (n=4634, age 4–5 years at wave 1). Medication coverage was defined as the proportion of time between the first and the last redeemed prescriptions in which the child was taking medication. Associations between predictor variables (child sex, ADHD symptom severity, age at first prescription, family socioeconomic status (SES), single parent status, parent education and parent mental health) and medication coverage were examined using regression analyses. <h3>Results</h3> 166 (3.6%) children had ever redeemed a prescription for an ADHD medication. Boys had higher odds of having taken ADHD medication than girls (OR=3.9; 95% CI 2.7 to 5.7). The mean medication coverage was 59.8%. Medication coverage was lower in children from families of lower SES (β=4.0; 95% CI 0.2 to 7.8, p=0.04). Medication coverage was relatively high in the first year of prescription, then decreased progressively, only increasing again after 5 or 6 years of treatment. <h3>Conclusions</h3> Children with ADHD from socially disadvantaged families were less likely to receive medication consistently. Prescribers need to continue to support families over many years to ensure medication is used consistently for children with ADHD.
“DOES GOD FIX THE DEATH-RATE?”
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
Authors: Katrina H. Smith, Eudocia Quant Lee, Alona Muzikansky, Elizabeth Robins Gerstner, Dan G. Duda, David A. Reardon, Lakshmi Nayak, Andrew David Norden, Lisa M. Doherty, Jennifer Rifenburg, Debra C. LaFrankie, Sandra Ruland, Julee Pulverenti, Deirdre Stokes, Priscilla Lam, Christine Sceppa McCluskey, Sarah C. Gaffey, Tracy Batchelor, Rakesh K. Jain, Patrick Y. Wen
Journal: Journal of Clinical Oncology (2014)

2031 Background: Although anti-angiogenic therapy for high-grade glioma (HGG) is promising, responses are not durable. The SDF-1/CXCR4 axis may help mediate resistance to VEGFR inhibition. SDF-1 is a known mediator of cancer cell invasion, vasculogenesis and vessel co-option. Plerixafor is a reversible CXCR4 inhibitor that has demonstrated growth inhibition in orthotopic glioblastoma xenografts. Methods: We conducted an open-label Phase I study to determine the safety and tolerability of plerixafor in combination with bevacizumab 10 mg/kg every two weeks in patients with recurrent HGG. In Part 1 of the study, plerixafor was dosed on Days 1-21 of each 28 day cycle. A 3 x 3 dose escalation design to a maximum planned dose level of plerixafor 320 µg/kg on Days 1-21 and bevacizumab 10 mg/kg on Days 1 and 15 of each 28 day cycle was used. Dose limiting toxicities (DLTs) were determined during the initial 4 weeks of therapy and included drug-related Grade ≥ 3 non-hematologic toxicities and Grade ≥ 4 hematologic toxicities. Results: 17 patients have been enrolled into Part 1 of the study to date: median age was 54 (23-67), median Karnofsky Performance Status was 90 (70-100), 9 were women (52.9%) , 9 had grade 4 glioma (52.9%), 8 had grade 3 glioma (47.1%), median number of prior therapies 1 (1-3). One DLT (grade 3 rectal fistula) was seen at a dose level of plerixafor 240 µg/kg + bevacizumab and the cohort was expanded to from 4 to 8 patients. Because no further DLTs were seen at the 240 µg/kg dose level, the maximum planned dose level of plerixafor 320 µg/kg + bevacizumb opened and 6 patients have been treated to date. Since no DLTs have been seen, the cohort has now been expanded to 12 patients. There are no other treatment-related grade 3 and no grade 4 toxicities. One grade 1 stroke (attributed to bevacizumab, unrelated to plerixafor) was found incidentally on imaging and the patient was removed from active treatment. Conclusions: Combination treatment with bevacizumab and plerixafor is well tolerated in HGG patients. No DLT has been seen in the first 6 patients treated at the maximum planned dose level (plerixafor 320 µg/kg on Days 1-21 and bevacizumab 10 mg/kg on Days 1 and 15 of each 28 day cycle) and the cohort has been expanded to 12 patients. Updated results will be presented. Clinical trial information: NCT01339039.
My Heroes
Authors: Nina K. Regevik
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Periarteritis nodosa in the kidney. Recovery following immunosuppressive therapy
Authors: S. Tuma
Journal: JAMA (1976)

ALTHOUGH the kidneys are often involved in polyarteritis nodosa (PAN),<sup>1-4</sup>acute renal failure is uncommon in this condition and has an unfavorable course. The outcome of 27 cases of oliguric PAN described in the literature was uniformly fatal shortly after the onset of anuria.<sup>5-9</sup> Our patient had acute anuric PAN, with renal function partially restored after dialysis and combined prednisone-cyclophosphamide therapy. <h3>Report of a Case</h3> A 17-year-old girl was admitted to the hospital because of anuria. She had been well until three weeks earlier, when she noticed that she passed dark urine and had pedal edema. Four weeks earlier, she had had a sore throat and was treated with ampicillin. On admission, the patient was pale and dyspneic. She had peripheral edema (4+ ). Blood pressure was 210/130 mm Hg. Moist rales were present bilaterally, and a grade 3 systolic ejection murmur was heard over the precordium. The liver
Maternal, child health needs noted by two major national study groups
Authors: J. W. Zylke
Journal: JAMA (1989)

THE NUMBER, 38000, is almost incomprehensible, in the way that large numbers can be. But it only takes one of those 38 000 to portray the tragedy. One tiny baby with huge dark eyes, dwarfed by tubes, wires, and machinery; one of 38000 who will die before their first birthday. Remarkable progress has been made in reducing infant mortality since the turn of the century, from 100 deaths per 1000 live births in 1915 to 10 per 1000 in 1987 (<i>Pediatrics</i>. 1988;82:817-827). However, since 1980, the rate of decline in infant mortality has slowed. In addition, a large discrepancy exists between rates for different subgroups of the population. (The rate for blacks is twice that for whites, for example.) These worrisome trends are at least partly the result of inadequate prenatal care. It is widely agreed that prenatal care is effective in preventing low birth weight. It is also cost-effective.
Postural Diplopia: Residuum of the Decerebrate State
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contrasting Effects of Testosterone and Stanozolol on Serum Lipoprotein Levels
Authors: Paul D. Thompson
Journal: JAMA (1989)

Oral anabolic steroids produce striking reductions in serum concentrations of high-density lipoprotein (HDL) cholesterol. We hypothesized that this effect related to their route of administration and was unrelated to their androgenic potency. We administered oral stanozolol (6 mg/d) or supraphysiological doses of intramuscular testosterone enanthate (200 mg/wk) to 11 male weight lifters for six weeks in a crossover design. Stanozolol reduced HDL-cholesterol and the HDL<sub>2</sub>subfraction by 33% and 71%, respectively. In contrast, testosterone decreased HDL-cholesterol concentration by only 9% and the decrease was in the HDL<sub>3</sub>subfraction. Apolipoprotein A-I level decreased 40% during stanozolol but only 8% during testosterone treatment. The low-density lipoprotein cholesterol concentration increased 29% with stanozolol and decreased 16% with testosterone treatment. Stanozolol, moreover, increased postheparin hepatic triglyceride lipase activity by 123%, whereas the maximum change during testosterone therapy ( + 25%) was not significant. Weight gain was similar with both drugs, but testosterone was more effective in suppressing gonadotropic hormones. We conclude that the undesirable lipoprotein effects of 17-α-alkylated steroids given orally are different from those of parenteral testosterone and that the latter may be preferable in many clinical situations. (<i>JAMA</i>. 1989;261:1165-1168)
Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine
Authors: M. J. Silverstein
Journal: JAMA (1974)

CLINICALLY recognized malignant melanoma of the urinary bladder is rare, having occurred only twice in more than 1,200 patients with melanoma seen at Memorial Hospital, New York, between 1935 and 1963.<sup>1</sup> This report presents a case of melanoma metastatic to the urinary bladder in an immunocompetent patient without evidence of other metastatic foci. Successful treatment was achieved by intralesional injection of Galaxo-strain BCG vaccine. To our knowledge, this is the first reported case of transurethral intralesional immunotherapy. <h3>Report of a Case</h3> In January 1973, a 56-year-old white man underwent axillary node dissection. Twenty-one of 32 lymph nodes contained melanoma (no primary was found). Postoperatively, he received weekly immunotherapy with BCG vaccine plus an allogenic tumor-cell vaccine and became PPD tuberculin-positive on this regimen. He remained free of disease until August 1973 when painless hematuria developed. Cystoscopic examination showed no abnormalities except for a black, discrete, round, 2-cm tumor mass
Tuberculin conversion in Indochinese refugees
Authors: D. Bickel
Journal: JAMA (1983)

<h3>In Reply.—</h3> Ms Bickel's remarks concerning problems with a batch of Aplisol are appreciated and deserve comment. We fully share her concern about the faulty Aplisol with its attendant potential for misdiagnoses and unnecessary treatment. Her concern gives us an opportunity to elaborate further on a substantial problem that has not been adequately reported in the scientific literature. The Aplisol problem first surfaced in 1982 when the CDC received reports from medical providers of increased rates of false-positive tuberculin reactions with certain lots of Aplisol used for Mantoux PPD skin tests. We investigated several clusters of false-positive tuberculin reactions associated with some lots of Aplisol and reported both our own and the CDC's findings in the August and October editions of the New York State Department of Health's<i>Disease Control Bulletin</i>.<sup>1,2</sup>In one specific investigation of a cluster of ten Aplisol PPD conversions, no evidence of a tuberculosis source
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Authors: A Krishnan, P Kapoor, J M Palmer, N-C Tsai, S Kumar, S Lonial, M Htut, C Karanes, N Nathwani, M Rosenzweig, F Sahebi, G Somlo, L Duarte, J F Sanchez, D Auclair, S J Forman, J G Berdeja
Journal: Leukemia (2017)
Developing gap in immunity to poliomyelitis in an urban area
Authors: J. L. Melnick
Journal: JAMA (1969)

Paralytic poliomyelitis reappeared in Houston in 1968 after a five-year period during which the city was free from the disease. Results of serological study indicate that in 1968 a large segment of children in low-income families were susceptible to infection by poliovirus, with as many as 62% of infants 3 to 8 months old lacking antibody against any type of poliovirus, and with 32% completely susceptible even at ages 12 to 23 months. Comparison with findings of a similar study carried out shortly after Houston's 1962 mass vaccination campaign indicates that a wide and disturbing immunity gap is developing in this sector of the population. There is clearly a need for longitudinal surveillance of polio immunity, and for concerted efforts to assure continuing vaccination of infants and young children, particularly in the lower socioeconomic group.